Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-10-02
2007-10-02
Rao, Deepak (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S365000, C514S374000, C546S269700, C548S202000, C548S203000, C548S235000, C548S236000
Reexamination Certificate
active
10192055
ABSTRACT:
Provided herein are novel substituted thiazoles and oxazoles of the Formula (I):as well as compositions, including pharmaceutical compositions, containing the same, and the use thereof in the treatment of various neurological and psychological disorders, e.g., affective disorder, anxiety and depression, treatable by antagonizing CRF receptors.
REFERENCES:
patent: 5464847 (1995-11-01), Courtemanche et al.
patent: WO92/16527 (1992-10-01), None
patent: WO95/10506 (1995-04-01), None
patent: WO97/35539 (1997-10-01), None
patent: WO97/35846 (1997-10-01), None
patent: WO97/44308 (1997-11-01), None
patent: WO98/03510 (1998-01-01), None
patent: WO99/01439 (1999-01-01), None
patent: WO99/01454 (1999-01-01), None
patent: WO99/11643 (1999-03-01), None
patent: WO99/51608 (1999-10-01), None
patent: WO 00/01675 (2000-01-01), None
Kasahara et al., English Translation of WO 92/16527 published Oct. 1992.
Mitchell, PubMed Abstract (Neurosci Biobehav Rev. 22(5):635-51) Sep. 1998.
J. Rivier et al., Proc. Nat. Acad. Sci. (USA), 80:4851 (1983).
W. Vale et al., Science, 213:1394 (1981).
W. Vale et al., Rec. Prog. Horm. Res., 39:245 (1983).
G.F. Koob, Persp. Behav. Med., 2:39 (1985).
E.B. Desouza et al., J. Neurosci., 5:3189 (1985).
J.E. Blalock, Physiological Reviews, 69:1 (1989).
J.E. Mortey, Life Sci., 41:527 (1987).
E.B. Desouza, Hosp. Practice, 23:59 (1988).
C.B. Nemeroff et al., Science, 226:1342 (1984).
C.M. Banki et al., Am. J. Psychiatry, 144:873 (1987).
R.D. France et al., Biol. Psychiatry, 28:86 (1988).
M. Arato et al., Biol. Psychiatry, 25:355 (1989).
C.B. Nemeroff et al., Arch. Gen. Psychiatry, 141:619 (1984).
F. Holsboer et al. Psychoneuroendocrinology, 9:147 (1984).
P.W. Gold et al., New Eng. J. Med., 314:1129 (1986).
R.M. Sapoisky, Arch. Gen. Psychiatry, 46:1047 (1989).
Grigoriadis et al., Neuropsychopharmacology, 2:53 (1989).
D.R. Britton et al., Life Sci., 31:363 (1982).
C.W. Berridge and A.J. Dunn, Regul. Peptides, 16:83 (1986).
C.W. Berridge and A.J. Dunn, Horm. Behav., 21:393 (1987).
Brain Research Reviews, 15:71 (1990).
K.T. Britton et al., Psychopharmacology, 86:170 (1985).
K.T. Britton et al., Psychopharmacology, 94:306 (1988).
N.R. Swerdlow et al., Psychopharmacology, 88:147 (1986).
G.F. Koob and K.T. Britton, Corticotripin-Releasing Factor: Basic and Clinical Studies of a Neuropeptide, E.B. Desouza and C.B. Nemeroff eds., CRC Press, p. 221 (1990).
C. Maillot et al., Gastroenterology, 119, 1569-1579 (2000).
J.R. McCarthy et al., Cuur. Pharm. Res., 5, 289-315 (1999).
P.J. Gilligan et al., J. Medicinal Chem., 43, 1641-1660 (2000).
G.P. Chrousos, Int. J. Obesity, 224, Supp 2, S50-S55 (2000).
E. Webster et al., Ann. N.Y. Acad. Sci., 840, 21-32 (1998).
D.J. Newport and C.B. Nemeroff, Cuur. Opin. Neurobiology, 10, 211-218 (2000).
G. Mastorakos and I. Ilias, Ann. N.Y. Acad. Sci., 900, 95-106 (2000).
M.J. Owens and C.B. Nemeroff, Expert Opin. Invest. Drugs, 8, 1849-1858 (1999).
G.F. Koob, Ann. N.Y. Acad. Sci., 909, 170-185 (2000).
Remington's Pharmaceutical Sciences, 17thed., Mack Publishing Co, Easton, PA, 1985, p 1418.
Hall et al., J. Org. Chem., 52, 3901-3904 (1987).
J. Med. Chem., 34, 267-276 (1991).
MacGregor et al., J. Org. Chem., 21, 1120-1123 (1956).
M. Fedorynski et al., Org. Prep. Proc. Int., 355-359 (1995).
F. Bailly et al., J. Chem. Soc. Perkin Trans., 1, 2983-2988 (1997).
G. Schwarz, Org. Synth., Coll. vol. 111, 332 (1955).
Wiley et al., Org. Reactions, 6, 367 (1951).
Zeng et al., Combinatorial Chemistry & High Throughput Screening, 1, 101 (1998).
Zeng et al., J. Chromatogr., 794, 1-13 (1998).
Grootenhuis Peter
Mao Long
Molteni Valentina
Termin Andreas
Wilson Dean
Bristol-Myers Squibb Pharma Company
Makujina Shah R.
Rao Deepak
Woodcock & Washburn LLP
LandOfFree
Substituted thiazoles and oxazoles as corticotropin... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted thiazoles and oxazoles as corticotropin..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted thiazoles and oxazoles as corticotropin... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3879104